ConCallIQ
Go Pro

HUL FY26 Annual Earnings Summary

4 quarters covered · ₹48,735 Cr revenue · ₹5,556 Cr PAT · 23.1% average EBITDA margin.

Total annual revenue: ₹48,735 Cr
Annual PAT: ₹5,556 Cr
Average margin: 23.1%
Promise delivery: 8%

Quarter-by-quarter progression

QuarterRevenuePATMarginSentiment
Q1 FY26₹16,323 Cr22.8%neutral
Q2 FY26₹16,061 Cr23.2%neutral
Q3 FY26₹2,562 Cr23.3%bullish
Q4 FY26₹16,351 Cr₹2,994 Cr23.0%bullish

Management promises made during the year

EBITDA margin guidance of 22%-23% for next 2-3 quarters

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY26
missed
First half of FY26 to be better than second half of FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY26
missed
Price growth expected in low single-digit range

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY26
missed
Gross margin expected to moderate further

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q1 FY26
missed
EBITDA margin guidance of 22%-23% for near term

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY26
missed
First half FY26 better than second half FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY26
missed
Low single-digit price growth if commodities stay in current range

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY26
missed
H2 growth better than H1

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY26
missed
EBITDA margin guidance 22%-23%

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY26
missed
Low single-digit price growth expected

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY26
missed
Ice cream demerger timeline

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY26
missed
H2 FY26 better than H1 FY26

Current-quarter commentary contains related evidence, but delivery is not conclusive enough for a clean met verdict.

Q4 FY26
close
EBITDA margin to stay in 22-23% range

Current-quarter results and commentary indicate the prior promise was delivered or materially on track.

Q4 FY26
met

Risks flagged during the year

Q3 FY26 · high

Depreciating rupee and divergent commodity trends (palm oil, tea, crude derivatives) could pressure margins if price increases lag.

Q4 FY26 · high

Crude-linked commodity costs and rupee depreciation could increase input costs beyond current 8-10% inflation, pressuring margins.

Q1 FY26 · medium

Management acknowledged price decreases in home care due to both commodity deflation and competitive pressures, which could pressure margins and pricing power.

Q1 FY26 · medium

Both brands remain in decline despite relaunches; management expects improvement over 'a few quarters' but no specific timeline, posing risk to Beauty & Wellbeing growth.

Q1 FY26 · medium

Analyst questioned the widening gap between NMI and pricing; management termed it transitory but acknowledged it could take time to normalize, especially if commodity prices turn inflationary.

Q2 FY26 · medium

GST transition impact may extend beyond October, with trade restocking taking a couple of months to normalize.

Q2 FY26 · medium

Prolonged monsoon and potential weak winter could dampen demand for seasonal products like skincare and ice cream.

Q2 FY26 · medium

Analyst raised concern about digital-first competition and need to focus on mid and bottom of pyramid; management acknowledged need for sharper segmentation.

Q3 FY26 · medium

Home care pricing has been negative for an extended period due to competitive intensity; recovery may be gradual.

Q3 FY26 · medium

Analyst noted HUL's skincare growth is meaningfully lower than platforms like Nykaa; management attributed to portfolio breadth but did not quantify gap.

Q4 FY26 · medium

Below-normal monsoon forecast (92%) could affect rural incomes and demand, though reservoir levels and MSPs provide some buffer.

Q4 FY26 · medium

If competitors do not follow price hikes, HUL may need to absorb cost inflation or lose market share, potentially impacting margins.

What changed through the year

G

Q1 FY26 · EBITDA margin guidance of 22%-23% for near term

Management expects EBITDA margin to remain in the 22%-23% range for the next few quarters, with sequential gross margin improvement reinvested into the business.

G

Q1 FY26 · First half FY26 better than second half FY25

Growth guidance unchanged: H1 FY26 expected to be better than H2 FY25, with gradual recovery sustained.

G

Q1 FY26 · Low single-digit price growth if commodities stay in current range

If commodity prices remain within the current range, management anticipates low single-digit price growth.

G

Q1 FY26 · Ice cream demerger completion by Q4 FY26

The demerger of the ice cream business into Quality Walls India Limited is on track for completion by Q4 FY26, subject to approvals.

G

Q2 FY26 · H2 growth better than H1

Management expects second half of FY26 to deliver better growth than first half, driven by improving macros and internal initiatives.

G

Q2 FY26 · EBITDA margin guidance 22%-23%

Near-to-mid-term EBITDA margin guidance remains 22%-23%, with ice cream demerger adding 50-60 bps to reported margin from Q3.

G

Q2 FY26 · Low single-digit price growth expected

If commodity prices remain at current levels, management expects low single-digit price growth going forward.

G

Q2 FY26 · Ice cream demerger timeline

Ice cream demerger expected to complete in December quarter, with listing in Q4 FY26, subject to regulatory approvals.

G

Q3 FY26 · FY27 revenue growth better than FY26

Management expects FY27 top-line growth to exceed FY26, driven by improving macros and internal actions.

G

Q3 FY26 · H2 FY26 better than H1 FY26

Second half of FY26 is expected to show stronger growth than the first half, with Q3 as a normalized base.

G

Q3 FY26 · EBITDA margin to stay in 22-23% range

Consolidated EBITDA margin will remain within the guided range of 22-23% (excluding ice cream), as growth investments are prioritized.

G

Q3 FY26 · Low single-digit price increases expected over FY27

Calibrated price increases across portfolio, especially in home care, to offset input cost inflation.

G

Q4 FY26 · FY27 to be better than FY26

Management expects FY27 performance to exceed FY26, driven by portfolio transformation and execution improvements.

G

Q4 FY26 · Medium-term EBITDA margin guidance 22.5-23.5%

Margin guidance maintained at 22.5-23.5% for the medium term, with flexibility to operate at lower end if cost pressures persist.

G

Q4 FY26 · Price increases of 2-5% already taken

Calibrated price increases of 2-5% implemented across home care and personal care to offset input cost inflation.

G

Q4 FY26 · ₹2,000 crore capex in premium formats

Capital investment of ₹2,000 crore planned for expanding capacity in premium formats across home care, personal care, and beauty.